App-Quantinova.ai

Genomic/genetic testing patterns for patients with metastatic castrate-resistant prostate cancer: Results from a real-world study in the United States.

Andrea Leith - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Atezolizumab

Analysis of rectal dose during prostate stereotactic body radiotherapy in MR-guided radiotherapy.

Kobika Sritharan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Radical prostate radiotherapy and the use of androgen deprivation in the era of risk stratification: Does real-world practice follow the evidence?

Mark Prentice - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Tamim Niazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.

Syed A. Hussain - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

S588410

DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.

Simon J. Crabb - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

guadecitabine

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.

Norihiko Tsuchiya - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Carboplatin

Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.

Raghad Muhsin Abdul-Karim - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Atezolizumab

A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).

Thomas Powles - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Gemcitabine

Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.

Andrew James Weickhardt - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Adrucil injection

A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).

Matt D. Galsky - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Ticilimumab

Value for money in genitourinary oncology.

David Edward O Reilly - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Othon Iliopoulos - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

N/A

Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.

Jennifer Allison - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Ipilimumab

Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.

Jennifer Allison - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Inlyta

Prognostic value of simple blood biomarkers of systemic inflammation for metastatic renal cell carcinoma (mRCC) patients who undergo cytoreductive nephrectomy (CNx).

Jigi Moudgil-Joshi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

N/A

Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Sumanta K. Pal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Everolimus

MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study.

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Everolimus

Comparison of electronic cigarette vs. cigarette smoke extract on macrophage function

Kylie Belchamber - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts